Brookline Capital Markets Weighs in on INTS FY2030 Earnings

Intensity Therapeutics Inc. (NASDAQ:INTS) – Equities researchers at Brookline Capital Markets issued their FY2030 EPS estimates for Intensity Therapeutics in a report issued on Tuesday, April 14th. Brookline Capital Markets analyst K. Raja anticipates that the company will post earnings per share of $12.94 for the year. The consensus estimate for Intensity Therapeutics’ current full-year earnings is ($1.18) per share.

INTS has been the topic of a number of other research reports. Freedom Capital upgraded shares of Intensity Therapeutics from a “hold” rating to a “strong-buy” rating in a research report on Monday, March 30th. Wall Street Zen raised shares of Intensity Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, April 4th. Finally, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Intensity Therapeutics in a research note on Monday, December 22nd. One investment analyst has rated the stock with a Strong Buy rating, two have given a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat.com, Intensity Therapeutics has an average rating of “Moderate Buy” and an average target price of $37.50.

Intensity Therapeutics Stock Down 1.1%

Shares of NASDAQ INTS opened at $5.30 on Wednesday. Intensity Therapeutics has a 1 year low of $4.63 and a 1 year high of $50.00. The firm’s 50 day moving average price is $6.75 and its 200 day moving average price is $8.87. The firm has a market cap of $13.46 million, a P/E ratio of -0.34 and a beta of 3.65. The company has a debt-to-equity ratio of 0.01, a quick ratio of 5.92 and a current ratio of 5.92.

Intensity Therapeutics (NASDAQ:INTS) last announced its earnings results on Friday, March 27th. The company reported ($0.31) earnings per share (EPS) for the quarter.

Hedge Funds Weigh In On Intensity Therapeutics

A number of large investors have recently bought and sold shares of the stock. Geode Capital Management LLC raised its stake in Intensity Therapeutics by 77.8% during the fourth quarter. Geode Capital Management LLC now owns 460,248 shares of the company’s stock worth $189,000 after purchasing an additional 201,357 shares during the period. Mesirow Financial Investment Management Inc. raised its stake in shares of Intensity Therapeutics by 25.5% in the 4th quarter. Mesirow Financial Investment Management Inc. now owns 251,000 shares of the company’s stock valued at $103,000 after acquiring an additional 51,000 shares during the period. Legacy Advisors LLC purchased a new position in shares of Intensity Therapeutics in the 4th quarter valued at $63,000. State Street Corp raised its stake in shares of Intensity Therapeutics by 839.3% in the 4th quarter. State Street Corp now owns 136,200 shares of the company’s stock valued at $56,000 after acquiring an additional 121,700 shares during the period. Finally, Corient Private Wealth LLC purchased a new position in shares of Intensity Therapeutics in the 4th quarter valued at $41,000. Hedge funds and other institutional investors own 3.74% of the company’s stock.

Intensity Therapeutics Company Profile

Intensity Therapeutics, Inc, a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of cancer drugs to treat solid tumors. The company's lead product candidate is INT230-6, which is in Phase 2 clinical trial for the treatment of refractory solid tumors; and pancreatic, colon, bile duct, squamous cell carcinoma, sarcoma, breast, and liver cancers. It has a collaboration agreement with Merck Sharpe & Dohme Corp. to evaluate the combination of INT230-6 and Keytruda in patients with advanced pancreatic, colon, squamous cell, and bile duct malignancies; Bristol-Myers Squibb Company to evaluate the combination of INT230-6 with Yervoy in patients with advanced liver, breast, and sarcoma cancers; and Ottawa Hospital Research Institute and the Ontario Institute of Cancer Research to study INT230-6 in a randomized controlled neoadjuvant phase II study in women with early-stage breast cancer.